KNSA - Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A
IEX Last Trade
26.75
-0.010 -0.037%
Share volume: 227,263
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$26.76
-0.01
-0.04%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-03-02 | 2023-05-04 | 2023-08-01 | 2023-11-02 | 2024-02-28 | 2024-04-25 | |
| Total revenue | 26.972 M | 99.135 M | 61.884 M | 48.345 M | 71.473 M | 67.046 M | 83.395 M | 79.858 M | |
| Cost of revenue | 5.029 M | 6.937 M | 6.710 M | 7.036 M | 7.699 M | 9.088 M | 9.584 M | 10.583 M | |
| Gross profit | 21.943 M | 92.198 M | 55.174 M | 41.309 M | 63.774 M | 57.958 M | 73.811 M | 69.275 M | |
| 320.17% | -40.16% | -25.13% | 54.38% | -9.12% | 27.35% | -6.15% | |||
| Operating expenses | 37.639 M | 41.162 M | 41.605 M | 44.217 M | 52.942 M | 51.574 M | 56.791 M | 65.016 M | |
| Selling general and admin | 23.841 M | 24.677 M | 27.215 M | 29.045 M | 29.175 M | 34.468 M | 36.739 M | 38.682 M | |
| Research and development | 13.798 M | 16.485 M | 14.390 M | 15.172 M | 23.767 M | 17.106 M | 20.052 M | 26.334 M | |
| Total expenses | 46.340 M | 52.722 M | 55.837 M | 59.541 M | 74.627 M | 77.973 M | 83.314 M | 96.400 M | |
| 13.77% | 5.91% | 6.63% | 25.34% | 4.48% | 6.85% | 15.71% | |||
| Operating income | -19.368 M | 46.413 M | 6.047 M | -11.196 M | -3.154 M | -10.927 M | 81.000 K | -16.542 M | |
| Ebit | -19.368 M | 46.413 M | 6.047 M | -11.196 M | -3.154 M | -10.927 M | 81.000 K | -16.542 M | |
| Pretax income | -19.265 M | 46.735 M | 6.841 M | -9.364 M | -1.239 M | -8.499 M | 2.450 M | -14.276 M | |
| -342.59% | -85.36% | -236.88% | -86.77% | 585.96% | -128.83% | -682.69% | |||
| Income tax | 716.000 K | -177.358 M | 2.380 M | 2.906 M | -16.211 M | 5.356 M | -22.787 M | 3.428 M | |
| Net income basic | -19.981 M | 224.093 M | 4.461 M | -12.270 M | 14.972 M | -13.855 M | 25.237 M | -17.704 M | |
| 1,221.53% | -98.01% | -375.05% | 222.02% | -192.54% | 282.15% | -170.15% | |||
| Net income | -19.981 M | 224.093 M | 4.461 M | -12.270 M | 14.972 M | -13.855 M | 25.237 M | -17.704 M | |
| 1,221.53% | -98.01% | -375.05% | 222.02% | -192.54% | 282.15% | -170.15% |